Research programme: paracrine gene therapy - Renova

Drug Profile

Research programme: paracrine gene therapy - Renova

Alternative Names: RT-110; RT-200; RT-210; RT-220; RT-230; RT-300; Urocortin-2 gene therapy - Renova

Latest Information Update: 23 Feb 2017

Price : $50

At a glance

  • Originator University of California, San Diego
  • Developer Renova Therapeutics
  • Class Gene therapies
  • Mechanism of Action Adenylate cyclase stimulants; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Heart failure; Non-alcoholic fatty liver disease; Obesity; Type 2 diabetes mellitus

Most Recent Events

  • 21 Feb 2017 Renova Therapeutics has patent protection for Urocortin 2 gene construct in USA
  • 08 Dec 2016 Renova Therapeutics in-licenses an adeno-associated virus (AAV) vector from Stanford University
  • 11 Oct 2016 Renova Therapeutics in-licenses Urocortin3 gene patent from Research Development Foundation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top